L1CAM. Among the novel targets not previously associated with RMS before, targeting approaches are most advanced for L1CAM, which is highly and consistently overexpressed in neuroblastoma [67,68,69], ovarian cancer [70,71], and testicular germ cell tumors [72]. This evidence concerns the gene L1CAM and ovarian carcinoma.